Drugs / GB5005
GB5005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06875063 | Apr → May 2026 overdue | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB5005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06875063 ↗ |
| Known as | GB5005 CART | “Drug: GB5005 CART” NCT06875063 ↗ |
| Known as | GB5005 chimeric antigen receptor T-cell injection | “GB5005 chimeric antigen receptor T-cell injection” NCT06875063 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell injection” NCT06875063 ↗ |
| Route | Intravenous | “cells will be slowly infused intravenously” NCT06875063 ↗ |